DRFP propoint obturation points are designed for permanent sealing of root canals when used with DRFP smartpaste Dental Sealer or Brasseler USA EndoSequence® BC Sealer following established endodontic procedures by qualified healthcare professionals.

Device Description

The propoints are identical to the points cleared for marketing with K100248. They are made of a radiopaque core and an opaque hydrophilic coating of cross-linked hydrophilic polymers that have been used in the contact lens industry for more than 20 years.

propoints are offered in the traditional 4% and 6% sizes and for use with variable taper files (such as ProTaper™ and Sendoline S5™). They are biocompatible and fully opaque. The hydrophilic coating expands radially to push the sealer into irregularities and voids present in the root canal system for a tight mechanical seal with the dentine. The coating only expands into available space and does not exert pressure on tooth structures. Dimensional length stability is maintained.

The points are packaged in clean room conditions and come individually wrapped to prevent cross-contamination. They can be cut to exact tip size and length.

No heating or compression equipment is required. Post insertion can commence immediately after root canal has been filled. The hydrophilic properties of the device allow extraction without softeners in revision procedures.

propoints are

coated with DRFP smartpaste prior to insertion into the root canal . (K100248) or
inserted after the root canal has been filled with EndoSequence® BC. .

AI/ML Overview

This report describes the acceptance criteria and study that proves the device meets the acceptance criteria for DRFP Ltd.'s Propoints with iRoot SP Sealer.

1. Table of Acceptance Criteria and Reported Device Performance

Acceptance Criteria	Reported Device Performance
Effective bonding with dentin and dentin tubules in root canal	Yes
Meets Bench Test Criteria in Dye Ingress Test	Yes (No sign of dye ingress after sectioning and assessment under a microscope in in-vitro dye penetration tests using heat-sterilized extracted teeth filled with EndoSequence® and propoints and immersed in Brilliant Blue Dye solution for at least one week.)
Effect of Interaction with Sodium Hypochlorite / EDTA residual levels after rinsing 3 times	None (Remaining 0.01% sodium hypochlorite after rinsing 3 times had no effect; undiluted 17% EDTA had no effect on the system.)
Biocompatible	Yes (Materials shown to be non-toxic, non-carcinogenic, and biocompatible with tissue fluids according to ISO 10993 and ISO 7405.)
Reported Failure Rate in Clinical Use	0.8% (Out of approximately 2000 treatments, predominantly attributed to tooth rather than material problems.)
Radiopacity in Clinical X-rays	Good (Clinical X-rays validate excellent radiopacity of both devices and confirm effective bonding to tooth structures and provide evidence of good healing.)

2. Sample Size Used for the Test Set and Data Provenance

Test Set Sample Size: Approximately 2000 treatments were reviewed for clinical performance.
Data Provenance: The clinical data is retrospective, derived from the "DRFP User Panel of practicing dentists". The country of origin for the data is not explicitly stated, but the submission is from DRFP Ltd. in the United Kingdom and their "User Panel" is mentioned, implying data collected from dental practices.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of those Experts

Number of Experts: A "DRFP User Panel of practicing dentists" was used. The exact number of dentists on this panel is not specified.
Qualifications of Experts: They are described as "practicing dentists." Their specific qualifications (e.g., years of experience, specialization) are not detailed in the provided text.

4. Adjudication Method for the Test Set

The document does not describe a formal adjudication method (e.g., 2+1, 3+1). The failure rate and clinical observations appear to be reported directly by the "DRFP User Panel of practicing dentists."

5. If a Multi Reader Multi Case (MRMC) Comparative Effectiveness Study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

There is no mention of an MRMC comparative effectiveness study, nor is AI involved in this device. This submission is for a conventional medical device (root canal obturation points and sealer).

6. If a Standalone (i.e. algorithm only without human-in-the-loop performance) was done

This question is not applicable as the device is a physical medical device (root canal obturation system), not an algorithm or AI.

7. The Type of Ground Truth Used

For Clinical Performance: The ground truth for clinical performance (failure rate, healing, bonding effectiveness) was established through observations and reporting by a "DRFP User Panel of practicing dentists" and confirmed through "clinical x-rays."
For Bench Tests: The ground truth for bench tests (dye penetration, sodium hypochlorite/EDTA interaction, radiopacity) was based on laboratory measurements and visual assessment (e.g., microscopic assessment for dye ingress).
For Biocompatibility: Ground truth was established by testing according to ISO 10993 and ISO 7405 standards.

8. The Sample Size for the Training Set

There is no mention of a "training set" in the context of an algorithm or AI. This submission is for a physical medical device, not an AI/ML product.

9. How the Ground Truth for the Training Set was Established

This question is not applicable as there is no "training set" for an algorithm.

Summary

{0}------------------------------------------------

DRFP Ltd.

Propoints with iRoot SP Sealer Traditional 510(k)

:K12-0048

JUN 20 2012

510(k) SUMMARY of Safety and Effectiveness 5. [21 CFR 807.92]

5.1 Submitter [807.92 (a)(1)]

DRFP Ltd. Villa Farm Jack Haws Lane BARNACK, Stamford Lincs. PE9 3DY United Kingdom Telephone Telefax e-mail
44 1780 740 574 44 - 1780 - 749 168 info@smart-seal.co.uk www.smart-seal.co.uk

5.2 Submission Correspondent 1807.92 (a)(1)]

Dagmar Maeser ·Business Support International
web
Amstel 320-l
1017 AP AMSTERDAM
Netherlands

Telephone	31 - 20 - 428 9591
Cell	31 - 651 41 5839 / 1 (828) 337-4550
Fax	31 - 20 - 201 0175
e-mail	bsi@xs4all.nl

5.3 Date Summary Prepared {807.92 (a)(1)] December 29, 2011

e-mail

Device Names [807.92 (a)(2)] DRFP propoints (4%, 6%, PT, S) 1 Proprietary

Model Numbers

4%	0.25-CMX001, 0.30-CMX011, 0.35-CMX012, 0.40-CMX013, 0.45-CMX014
6%	0.25-CMX002, 0.30-CMX021, 0.35-CMX022, 0.40-CMX023, 0.45-CMX024
PT	F1-CMX031, F2-CMX032, F3-CMX033, F4-CMX034, F5-CMX035
S	S2-CMX061, S3-CMX062, S4-CMX063

Root Canal Obturation Points Common
Classification Names Resin, Root Canal Filling

Class II CFR 872.3820 Product Code/ CFR KIF

Component of ProSmart Root Canal Obturation System K100248 -

5 - 510(k) Summary - 1/4

{1}------------------------------------------------

ફ.ક Reason for Submission [807.81(3)(i)]

To submit bench & clinical performance data to demonstrate that the previously cleared DRFP propoints (4%, 6%, PT, S - K100248) are safe and effective for the obturation of root canals when used with

Innovative BioCeramix iRoot SP Sealer (K080917) marketed in the United States by

Brasseler USA Dental L.L.C. as EndoSequence® BC.

Predicate Device [807.92(a)(3)}

. K100248

Obturation System

DRFP ProSmart Root Canal

propoints (4%, 6%, PT, S) Obturation Points smartpaste Sealer with Active Powder

5.7 Device Description [807.92(a)(4)]

propoint Obturation Points 5.7.1

The points are packaged in clean room conditions and come individually wrapped to prevent cross-contamination. They can be cut to exact tip size and length.

propoints are

coated with DRFP smartpaste prior to insertion into the root canal . (K100248) or
inserted after the root canal has been filled with EndoSequence® BC. .

To demonstrate the safety and effectiveness of root obturations with this sealer is the subject of this submission.

EndoSequence® BC Sealer 5.7.2

NOTE: Only the interaction with this sealer, not the device itself, is the subject of this submission.

It "is a convenient premixed ready-to-use injectable white hydraulic cement paste developed for permanent root canal filling and sealing applications. EndoSequence® BC (iRoot SP) is an insoluble, radiopaque and aluminum-free material based on a calcium silicate composition, which requires the presence of water to set and harden. The sealer does not shrink during setting and demonstrates excellent physical properties." 2

Quoted from K080917 iRoot SP Summary, Innovative BioCeramix, Inc.

{2}------------------------------------------------

5.8 Statement of Intended Use [807.92(a)(5)]

DRFP propoint obturation points are designed for permanent sealing of root canals when used with DRFP smartpaste dental sealer or with EndoSequence® BC Sealer following established endodontic procedures by qualified healthcare professionals.

Federal US Law restricts propoints (K100248) and Brasseler EndoSequence® BC (K080917) to sale by or on the order of a dentist.

Comparison with Predicate Devices [807.92(a)(6)] 5.9

The use of propoints with Brasseler EndeSequence® BC Sealer for root canal obturations is substantially equivalent to the performance of the DRFP ProSmart Root Canal Obturation System (K100248).

	DRFPpropointsw/BrasselerEndoSequence® BC	DRFPProSmartSystemK100248
Effectively bonds withdentine and dentinetubules in root canal	Yes	Yes
Meets Bench TestCriteria in DyeIngress Test	Yes	Yes
Effect of Interactionwith SodiumHypochlorite / EDTAresidual levels afterrinsing 3 times	None	None
Biocompatible	Yes	Yes
Reported FailureRate in Clinical Use3	0.8%	1.0%
Radiopacity in ClinicalX-rays	Good	Good

5.10 Performance Data (807.92(b)]

5.10.1 BenchTests (807.92(b)(1)

DRFP propoints used with EndoSequence® BC Sealer:

In-Vitro Dye Penetration and Sealing Test to Validate 1) Effective Seal
Heat-sterilized extracted teeth (more brittle and desiccated than patients' teeth), filled with EndoSequence® and propoints and immersed in Brilliant Blue Dye solution for at least one week, showed no sign of dye ingress after sectioning and assessment under a microscope.

..............................................................................................................................................................................

ー・・・・・・・・・・・・・・・・・・・・・・・・・・

Includes immediate tooth failures such as fracturing, canal ossification, teeth requiring extraction n

{3}------------------------------------------------

2) Exposure to Sodium Hvpochlorite

The manufacturer recommends to rinse the canal three (3) times prior to insertion of the endodontic components. If this regime is followed, the remaining value of 0.01% sodium hypochlorite will have no effect on the safety and effectiveness of the devices.

3) Exposure to EDTA

Undiluted 17% EDTA has shown to have no effect on the system. 4) Radiopacity
- Clinical x-rays validate the excellent radiopacity of both devices.

5.10.2 Clinical Performance (807.92(b)(2)

18 months of clinical use demonstrate that propoint and EndoSequence® Sealer form an effective and safe system for the obturation of root canals. Out of approx. 2000 treatments, the DRFP User Panel of practicing dentists reports a 0.8% failure rate that is predominantly attributed to tooth rather than material oroblems. An abundance of clinical x-rays confirm effective bonding to tooth structures and provide evidence of good healing.

5.10.3 Conclusion (807.92(b)(3)

Bench test results and clinical evidence based on more than 2000 treatments performed by DRFP User Panel of practicing dentists, including x-rays, show that DRFP propoints with Brasseler USA EndoSequence ® BC sealer form an effective system for root canal obturations.

Contraindications 5.11

The manufacturer recommends to not use the system in pregnant women and in nursing mothers.

5.12 Information Bearing on Safety and Effectiveness [807.92 (b)(3)]

. . . .

The materials used in DRFP propoints and EndoSequence® BC Sealer have a long history of safe and effective use in dental and other medical devices.

Biocompatibility testing according to ISO 10993 and ISO 7405 has shown the materials to be non-toxic, non-carcinogenic and biocompatible with tissue fluids . There are no characteristics known that should adversely affect the safety and effectiveness of this device combination.

Performance bench test results and abundant clinical data demonstrate that DRFP propoints in combination with Brasseler USA EndoSequence® BC Sealer form an effective and safe system for the obturation of dental root canals and that it is substantially equivalent to the predicate.

The results of design validation and non-clinical and clinical performance testing raise no new issues of safety and effectiveness.

5 - 510(k) Summary -

As demonstrated in K080917 (iRoot SP) and K100248

{4}------------------------------------------------

Image /page/4/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo is a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" arranged around the perimeter. Inside the circle is a stylized image of an eagle or other bird-like figure, composed of three curved lines that suggest the head and wings. The logo is black and white.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002

DRFP. Limited C/O Ms. Dagmar Maser Regulatory Consultant, Medical Devices Maeser Business Support International, V.O.F Amstel 320-I 1017 AP Amsterdam NETHERLANDS

JUL 12 2012

Re: K120048

Trade/Device Name: DRFP Propoints 4%, 6%, PT, S+ Extension of Labeling for use with Brasseler USA EndoSequence® SP2 Regulation Number: 21 CFR 872.3820 Regulation Name: Root Canal Filling Resin Regulatory Class: II Product Code: KIF Dated: June 14, 2012 Received: June 18, 2012

Dear Ms. Maser:

This letter corrects our substantially equivalent letter of June 20, 2012.

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

{5}------------------------------------------------

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to

http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours.

Susan Bunner

Anthony D. Watson, B.S., M.S., M.B.A. Director Division of Anesthesiology, General Hospital, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{6}------------------------------------------------

DRFP Ltd.

Section 4 INDICATIONS FOR USE

510(k) Number (if known):

Device Name:

DRFP propoints 4%, 6%, PT, S¹ Extension of Labeling for Use with Brasseler USA EndoSequence® SP2

INDICATIONS FOR USE:

Prescription Use X (Part 21 CFR 801 Subpart D) AND/OR

Over-The-Counter Use (21 CFR 807 Subpart C)

(Please DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Susan Russo

Division Sign-Off) Division of Anesthesiology, General Hospital · fection Control, Dental Devices

510(k) Number: K120048

Concurrence of CDRH, Office of Device Evaluation (ODE)

| K100248
R100246
2 US Brand Name for Innovative BioCcramix Inc. iRoot SP, K080917

1/1 | Page

Regulation Number and Section

§ 872.3820 Root canal filling resin.

(a)
Identification. A root canal filling resin is a device composed of material, such as methylmethacrylate, intended for use during endodontic therapy to fill the root canal of a tooth.(b)
Classification. (1) Class II if chloroform is not used as an ingredient in the device.(2) Class III if chloroform is used as an ingredient in the device.
(c)
Date PMA or notice of completion of a PDP is required. A PMA or a notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before December 26, 1996 for any root canal filling resin described in paragraph (b)(2) of this section that was in commercial distribution before May 28, 1976, or that has, on or before December 26, 1996 been found to be substantially equivalent to a root canal filling resin described in paragraph (b)(2) of this section that was in commercial distribution before May 28, 1976. Any other root canal filling resin shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.